Company news

Pacira BioSciences, Inc. news in 2024

Pacira BioSciences, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

December 5, 2024

Pacira Awarded New U.S. Patent Covering EXPAREL Composition

December 2, 2024

Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

November 13, 2024

Pacira BioSciences Reports Third Quarter 2024 Financial Results

November 5, 2024

Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings

November 3, 2024

Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024

October 29, 2024

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

October 20, 2024

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025

October 2, 2024

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

September 25, 2024

Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey

August 8, 2024

Pacira BioSciences Reports Second Quarter 2024 Financial Results

July 29, 2024

Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024

July 22, 2024

Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025

July 9, 2024

Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference

May 29, 2024

Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029

May 9, 2024

Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes

May 7, 2024

Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

May 6, 2024

Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program

May 6, 2024

Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024

April 29, 2024

Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

April 1, 2024

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

March 12, 2024

Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference

March 5, 2024

Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results

February 28, 2024

Pacira to Report 2023 Financial Results on Thursday February 29, 2024

February 21, 2024

Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

February 14, 2024

Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.

February 6, 2024

Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues

January 3, 2024

Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Calls in 2024

Decks in 2024